tirzepatide kidney damage SURPASS-4: slows disease in adults with type 2 diabetes, CV risk Next-generation therapeutics for diabetic kidney

However, adherence to physical activity remains a major challenge, often limited by perceived effort, time constraints, and lack of behavioral support

Figure 4)

Funding No funding or sponsorship was received for this study or the publication of this article

Therefore, the functional capacity of adipose tissue is now recognized as a critical determinant of metabolic health in obesity [7], shifting the therapeutic focus from merely reducing fat mass to improving adipose tissue quality and function

This dual-action approach enhances insulin sensitivity and further reduces appetite and fat storage, often leading to even more substantial weight loss than GLP-1-only therapies

Eli Lillys newest weight loss drug may also help sleep apnea according to Phase 3 data The same trial also revealed retatrutide could offer substantial relief for knee osteoarthritis pain, reducing it by up to 73.1% Bookmark CommentsGo to comments Eli Lilly has unveiled promising trial results for its experimental obesity drug, retatrutide, demonstrating its potential to significantly reduce sleep apnea severity, alleviate knee pain, and aid in weight loss